NYSE$GKOS
Glaukos Corp · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Glaukos reported strong Q4 2024 results with record net sales and improved financial performance.
Glaukos achieved record Q4 2024 net sales of $105.5 million, representing a 28% year-over-year increase. The company reported a net loss of $33.6 million, a reduction from the prior year's loss, while non-GAAP net loss improved to $22.2 million. Operating loss also narrowed, and the company ended the quarter with a strong cash position of $324 million.
- Q4 2024 net sales grew 28% year-over-year to $105.5 million.
- Glaucoma segment sales reached $84.1 million, up 39% year-over-year.
- Net loss narrowed to $33.6 million, with non-GAAP net loss at $22.2 million.
- Gross margin stood at 73%, while non-GAAP gross margin was 82%.
Headline financials
Revenue & EPS history
Glaukos · Revenue · Quarterly
$105M
Revenue by segment
Glaukos · $58.3M total across 1 segment · Q3 2023
- Glaucoma$58.3M+8.6%100.0%
Forward guidance
Glaukos expects continued strong growth in 2025, with net sales projected between $475 million and $485 million.
Tailwinds
- 2025 net sales guidance set between $475 million and $485 million.
- Continued strong demand for glaucoma treatment products.
- Ongoing expansion of proprietary, long-duration drug delivery technology.
- Improvement in operating efficiency and cost management.
- Solid financial position with strong cash reserves and no debt.
Headwinds
- Potential impact of macroeconomic conditions on revenue growth.
- Fluctuations in foreign exchange rates affecting international sales.
- Increased costs related to R&D and commercialization efforts.
- Competitive pressures in the ophthalmic pharmaceutical market.
- Regulatory uncertainties related to new product approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.3%
Avg return
Earnings day
-4.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
39%
18 / 46 earnings
Positive
+25.2%
Q1 2016
Best reaction
-28.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +22.1% | +14.1% | -11.8% | |
| Q4 2025 | +12.8% | +12.9% | -5.3% | |
| Q3 2025 | +14.0% | +11.5% | +37.9% | |
| Q1 2025 | -1.4% | -15.0% | -15.1% | |
| Q4 2024 | -20.0% | -23.4% | -35.0% | |
| Q3 2024 | -3.0% | +7.6% | +4.9% | |
| Q2 2024 | -0.2% | -3.6% | +13.6% | |
| Q1 2024 | +9.4% | +9.4% | +17.4% | |
| Q4 2023 | -0.7% | -0.5% | -4.4% | |
| Q3 2023 | -5.9% | -6.1% | -4.5% | |
| Q2 2023 | -3.0% | -2.0% | -2.4% | |
| Q1 2023 | +11.3% | +29.1% | +36.7% | |
| Q4 2022 | -2.7% | -5.4% | -1.7% | |
| Q3 2022 | -11.6% | -13.8% | -12.4% | |
| Q2 2022 | +0.4% | -1.8% | -8.3% | |
| Q1 2022 | -7.0% | -27.1% | -11.2% | |
| Q4 2021 | +1.9% | +9.7% | +10.3% | |
| Q3 2021 | +6.6% | -2.6% | -24.7% | |
| Q2 2021 | +3.8% | +2.4% | +20.2% | |
| Q1 2021 | -9.0% | -15.8% | -18.9% | |
| Q4 2020 | -1.9% | -0.4% | -11.3% | |
| Q3 2020 | +7.7% | +15.3% | +25.4% | |
| Q2 2020 | -13.2% | -18.6% | -3.4% | |
| Q1 2020 | -2.0% | -6.8% | +15.0% | |
| Q4 2019 | -28.2% | -30.2% | -45.6% | |
| Q3 2019 | -8.8% | -2.8% | -7.3% | |
| Q2 2019 | -15.4% | -20.5% | -14.9% | |
| Q1 2019 | -4.8% | -10.4% | -5.9% | |
| Q4 2018 | +11.6% | +2.7% | +17.9% | |
| Q3 2018 | +1.8% | -2.8% | +9.5% | |
| Q2 2018 | -9.5% | -7.5% | +57.1% | |
| Q1 2018 | -4.5% | -8.3% | +11.9% | |
| Q4 2017 | +7.1% | +0.8% | -2.1% | |
| Q3 2017 | -16.2% | -15.0% | -26.6% | |
| Q2 2017 | -6.7% | -5.0% | -3.9% | |
| Q1 2017 | -11.6% | -15.4% | -14.9% | |
| Q4 2016 | +4.8% | -1.4% | +12.7% | |
| Q3 2016 | -3.3% | -3.6% | -5.7% | |
| Q2 2016 | -2.1% | -5.5% | -14.6% | |
| Q1 2015 | +18.3% | — | — | |
| Q1 2016 | +25.2% | — | — | |
| Q4 2015 | -2.9% | — | — | |
| Q3 2014 | +9.6% | — | — | |
| Q3 2015 | +15.3% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q2 2015 | -0.0% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro